ANGPTL3 polyclonal antibody; host Rabbit; reactivity Human, Rat, Mouse
Know who made it. See the evidence. Buy through one marketplace.
similarity:Contains 1 fibrinogen C-terminal domain.,tissue specificity:Expressed principally in liver. Weakly expressed in kidney.,
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Species / reactivity | WB | ELISA |
|---|---|---|
| Human,Rat,Mouse |
This product is manufactured by Reed Biotech and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
ANGPTL3 (angiopoietin like 3), also known as angiopoietin-related protein 3 and ANG-5, is a liver-enriched secreted protein studied for its control of lipoprotein lipase activity, triglyceride clearance and systemic lipid metabolism.
Biological function: ANGPTL3 is secreted predominantly by the liver and can be proteolytically processed into N- and C-terminal fragments. Reviewed UniProt evidence supports a hepatokine role in lipid and glucose metabolism; ANGPTL3 raises plasma triglycerides in part by inhibiting lipoprotein lipase (LPL), reducing triglyceride clearance. NCBI also describes distinct functional contributions of its N-terminal lipid-metabolism region and C-terminal fibrinogen-like region.
